CAR T-Cell Therapy Clinical Trial Enrolling Patients With Myeloma
The University of Texas (UT) Southwestern Medical Center joins eight other sites in the United States that are enrolling patients with multiple myeloma for a clinical trial of chimeric antigen receptor (CAR) T-cell therapy.
“We are very excited to be pioneering this promising treatment for multiple myeloma in this region,” stated site investigator Larry Anderson, MD, PhD, Associate Professor of Internal Medicine with UT Southwestern’s Simmons Cancer Center. “These are patients who either did not respond to traditional treatments or who relapsed at least twice.”
At this time, two CAR T-cell immunotherapies have been approved by the U.S. Food and Drug Administration for hematologic malignancies. The first one is tisagenlecleucel, which is indicated for the treatment of children and young adults with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. The second one is axicabtagene ciloleucel, which is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.
Ted Laetsch, MD, Assistant Professor of Pediatrics at UT Southwestern Medical Center, led the only clinical trial site in the Southwest for tisagenlecleucel and is now treating patients younger than age 25 with ALL with this CAR T-cell therapy at the Pauline Allen Gill Center for Cancer and Blood Disorders at Children’s Health.
Patients with multiple myeloma interested in participating in this trial should call 214/645-HOPE (4673) and ask for Julie Zuckerman.